Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
334 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03284957 | Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer(AMEERA-1) | terminated | Phase 1 / Phase 2 | 136 | SanofiINDUSTRY | 10 | Nov 24, 2025 | clinicaltrials |
| NCT05117476 | A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors(MICA) | active not recruiting | Phase 1 | 440 | Cullinan Therapeutics Inc.INDUSTRY |
| 4 |
| Nov 24, 2025 |
| clinicaltrials |
| NCT03319940 | Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC) | active not recruiting | Phase 1 | 269 | AmgenINDUSTRY | 13 | Nov 19, 2025 | clinicaltrials |
| NCT06590961 | UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies | recruiting | Phase 1 | 94 | Ubix Therapeutics, Inc.INDUSTRY | 3 | Nov 19, 2025 | clinicaltrials |
| NCT03369223 | A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 356 | Bristol-Myers SquibbINDUSTRY | 11 | Nov 18, 2025 | clinicaltrials |
| NCT05364944 | A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)(OXTEND-01) | terminated | Phase 1 | 19 | Debiopharm International SAINDUSTRY | 8 | Nov 17, 2025 | clinicaltrials |
| NCT03656718 | A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) | completed | Phase 1 / Phase 2 | 139 | Bristol-Myers SquibbINDUSTRY | 12 | Nov 12, 2025 | clinicaltrials |
| NCT03468426 | A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours | completed | Phase 1 | 252 | Boehringer IngelheimINDUSTRY | 12 | Nov 10, 2025 | clinicaltrials |
| NCT02875548 | A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study(TRuST) | completed | Phase 1 / Phase 2 | 58 | Epizyme, Inc.INDUSTRY | 7 | Nov 4, 2025 | clinicaltrials |
| NCT05029882 | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab | active not recruiting | Phase 1 | 520 | AbbVieINDUSTRY | 10 | Oct 29, 2025 | clinicaltrials |
| NCT05469178 | A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene | terminated | Phase 1 / Phase 2 | 26 | BerGenBio ASAINDUSTRY | 7 | Oct 29, 2025 | clinicaltrials |
| NCT01592370 | An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 320 | Bristol-Myers SquibbINDUSTRY | 6 | Oct 22, 2025 | clinicaltrials |
| NCT03564691 | Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001) | completed | Phase 1 | 470 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Oct 7, 2025 | clinicaltrials |
| NCT04501614 | A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 11 | TakedaINDUSTRY | 15 | Oct 2, 2025 | clinicaltrials |
| NCT05319587 | Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 22 | Moleculin Biotech, Inc.INDUSTRY | 2 | Sep 30, 2025 | clinicaltrials |
| NCT06551064 | Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients(Dahlia) | active not recruiting | Phase 1 | 96 | Formycon AGINDUSTRY | 11 | Sep 4, 2025 | clinicaltrials |
| NCT04772989 | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies(ARC-12) | completed | Phase 1 | 94 | Arcus Biosciences, Inc.INDUSTRY | 3 | Aug 28, 2025 | clinicaltrials |
| NCT04210219 | A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia | completed | Phase 1 | 85 | Janssen Research & Development, LLCINDUSTRY | 7 | Aug 21, 2025 | clinicaltrials |
| NCT04657224 | A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia | completed | Phase 1 | 75 | Janssen Research & Development, LLCINDUSTRY | 12 | Aug 21, 2025 | clinicaltrials |
| NCT04876092 | A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL | completed | Phase 1 | 45 | Janssen Research & Development, LLCINDUSTRY | 4 | Aug 21, 2025 | clinicaltrials |
| NCT05109442 | Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers | terminated | Phase 1 / Phase 2 | 112 | Affimed GmbHINDUSTRY | 5 | Aug 20, 2025 | clinicaltrials |
| NCT05743036 | ZN-c3 in Adult Participants With Metastatic Colorectal Cancer | terminated | Phase 1 | 44 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY | 7 | Aug 8, 2025 | clinicaltrials |
| NCT03059823 | A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors | completed | Phase 1 | 325 | Incyte CorporationINDUSTRY | 16 | Aug 3, 2025 | clinicaltrials |
| NCT03729596 | MGC018 With or Without MGA012 in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 143 | MacroGenicsINDUSTRY | 4 | Jul 31, 2025 | clinicaltrials |
| NCT03104699 | A Study of AGEN2034 in Advanced Tumors and Cervical Cancer | completed | Phase 1 / Phase 2 | 211 | Agenus Inc.INDUSTRY | 9 | Jul 30, 2025 | clinicaltrials |
| NCT03853109 | AMG 404 in Patients With Advanced Solid Tumors | completed | Phase 1 | 171 | AmgenINDUSTRY | 13 | Jul 20, 2025 | clinicaltrials |
| NCT04740424 | FS222 First in Human Study in Patients With Advanced Malignancies | recruiting | Phase 1 | 260 | invoX Pharma LimitedINDUSTRY | 7 | Jul 1, 2025 | clinicaltrials |
| NCT03786926 | Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas | terminated | Phase 1 | 53 | HutchmedINDUSTRY | 6 | Jun 26, 2025 | clinicaltrials |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children(SCOUT) | active not recruiting | Phase 1 / Phase 2 | 154 | BayerINDUSTRY | 21 | Jun 22, 2025 | clinicaltrials |
| NCT03013491 | PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas | terminated | Phase 1 / Phase 2 | 196 | CytomX TherapeuticsINDUSTRY | 6 | Jun 17, 2025 | clinicaltrials |
| NCT06816017 | A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC) | withdrawn | Phase 1 | 0 | Hoffmann-La RocheINDUSTRY | 6 | Jun 16, 2025 | clinicaltrials |
| NCT02303821 | Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 1 | 141 | AmgenINDUSTRY | 33 | Jun 4, 2025 | clinicaltrials |
| NCT03970746 | Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC | active not recruiting | Phase 1 / Phase 2 | 73 | PDC*line Pharma SASINDUSTRY | 5 | May 29, 2025 | clinicaltrials |
| NCT02329847 | A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies | completed | Phase 1 / Phase 2 | 144 | Janssen Research & Development, LLCINDUSTRY | 6 | May 25, 2025 | clinicaltrials |
| NCT02799095 | A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors | completed | Phase 1 / Phase 2 | 243 | Mural Oncology, IncINDUSTRY | 7 | May 21, 2025 | clinicaltrials |
| NCT02632448 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | completed | Phase 1 / Phase 2 | 229 | Esperas Pharma Inc.OTHER | 4 | May 2, 2025 | clinicaltrials |
| NCT04495621 | MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)(C-PRECISE-01) | completed | Phase 1 / Phase 2 | 29 | Menarini GroupINDUSTRY | 7 | May 1, 2025 | clinicaltrials |
| NCT03008187 | MEN1703 (SEL24) in Participants With Acute Myeloid Leukemia(Diamond-01) | completed | Phase 1 / Phase 2 | 73 | Menarini GroupINDUSTRY | 4 | Apr 29, 2025 | clinicaltrials |
| NCT03110107 | First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 376 | Bristol-Myers SquibbINDUSTRY | 17 | Apr 24, 2025 | clinicaltrials |
| NCT03571568 | A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL | recruiting | Phase 1 / Phase 2 | 140 | BioInvent International ABINDUSTRY | 6 | Apr 24, 2025 | clinicaltrials |
| NCT02974725 | A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma | terminated | Phase 1 | 241 | Novartis PharmaceuticalsINDUSTRY | 11 | Apr 13, 2025 | clinicaltrials |
| NCT04630756 | AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer | completed | Phase 1 / Phase 2 | 40 | AstraZenecaINDUSTRY | 9 | Apr 9, 2025 | clinicaltrials |
| NCT03179436 | Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001) | completed | Phase 1 / Phase 2 | 415 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Apr 8, 2025 | clinicaltrials |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | terminated | Phase 1 / Phase 2 | 222 | Kymab LimitedINDUSTRY | 6 | Apr 2, 2025 | clinicaltrials |
| NCT05267470 | A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)(FORTITUDE-201) | terminated | Phase 1 | 74 | AmgenINDUSTRY | 8 | Mar 25, 2025 | clinicaltrials |
| NCT05543629 | A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 36 | Bristol-Myers SquibbINDUSTRY | 5 | Mar 18, 2025 | clinicaltrials |
| NCT05619744 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas | completed | Phase 1 | 41 | Hoffmann-La RocheINDUSTRY | 5 | Mar 10, 2025 | clinicaltrials |
| NCT03761017 | MGD019 DART® Protein in Unresectable/Metastatic Cancer | completed | Phase 1 | 162 | MacroGenicsINDUSTRY | 5 | Mar 6, 2025 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials